Blockade of the TIGIT-CD155/CD112 axis enhances functionality of NK-92 but not cytokine-induced memory-like NK cells toward CD155-expressing acute myeloid leukemia
Authors (first, second and last of 7)
Collection
Natural Killer cell therapy
View the webinar recording based on this Natural Killer Cell Therapy collection.
Adoptive transfer of natural killer (NK) cells has become a new paradigm in treatment of solid tumors. In contrast to cytotoxic T lymphocytes that recognize tumor antigen in the complex of MHC, NK cells target tumor cells that either have low or no MHC expression, which has been used by tumor cells to evade CTL attack. Thus, NK cell therapy can be an appropriate complemental therapy in treatment of tumors that escape CTL therapy. To that end, new strategies are needed to enhance the efficacy of the NK cell therapy. This collection will highlight studies in several key areas (but not limited in these areas) of NK cell research: (1) optimal culture and expansion method of NK cells that are aimed to maximize the clinical efficacy; (2) rational combination with targeted therapy agents, and immune checkpoint inhibitors; (3) NK cell-intrinsic factors that may directly or indirectly enhance the efficacy of NK cell therapy; (4) reports of clinical trials of NK cell therapy.
Please note this collection does not have a specific Guest Editor appointed and manuscripts are handled on a case by case basis by members of our editorial board. The peer review process for these articles is the same as the peer review process of the journal in general.
Articles (10 in this collection)
-
-
A “Prime and Expand” strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy
Authors (first, second and last of 26)
-
Intensified NK cell therapy in combination with low-dose chemoradiotherapy against human colorectal cancer
Authors (first, second and last of 10)
-
HLA-B*44 and the Bw4-80T motif are associated with poor outcome of relapse-preventive immunotherapy in acute myeloid leukemia
Authors (first, second and last of 8)
-
Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia
Authors (first, second and last of 15)
-
Therapeutic potential of FLT4-targeting peptide in acute myeloid leukemia
Authors (first, second and last of 5)
-
Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers
Authors (first, second and last of 13)
-
Different effects of NK cells and NK-derived soluble factors on cell lines derived from primary or metastatic pancreatic cancers
Authors (first, second and last of 9)
-
Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Authors (first, second and last of 4)
-
TCR extracellular domain genetically linked to CD28, 2B4/41BB and DAP10/CD3ζ -engineered NK cells mediates antitumor effects
Authors (first, second and last of 7)
